Sinopharm subsidiaries report mixed results for first quarter 2025

Sinopharm Group Co. Ltd. (HKEX:1099) has announced the principal unaudited accounting data and financial indicators for its subsidiaries, Sinopharm Accord and China National Medical Device Co., Ltd. (CNMDC), for the first quarter ended March 31, 2025. Sinopharm Accord reported revenue of RMB18.294 billion, a 4.17% year-on-year decrease, and net profit attributable to shareholders of RMB328 million, a 15.63% decrease. Basic earnings per share also declined by 15.71%. These declines were attributed to industry policy changes, intensified market competition, and delays in downstream payments leading to increased provisions for bad debts.